Human Genome Sciences Inc. has signed 20 material transferagreements with 14 research institutes and hospitals to identify newdrug and diagnostic targets.Bradley Lorimier, Human Genome's senior vice president for businessdevelopment, said, "We will give the institutions access to our genesequencing information and in some cases the actual genes or theproteins expressed for those genes and they will use that informationfor research in areas where they have expertise."Under terms of the agreements, Human Genome retains proprietaryrights to its information and the right to license any patentableinventions made by the institutes with the data. The institutes'scientists get the rights to publish their findings.In May, Human Genome, of Rockville, Md., signed 10 similaragreements, giving the company a total of 30 at 16 institutions. (Seethe May 5, 1994 issue of BioWorld Today.)Collaborations announced Thursday, including the specific researchareas, are: Boston University School of Medicine (lung andneurodegenerative diseases); Mayo Clinic, Rochester, Minn., (prostatecancer); Oregon Health Sciences University, Portland, (cellulardetoxification); Pennsylvania State University, Hershey, (proteintransport); McGill University, Montreal, (transcription factors);Oklahoma Medical Research Foundation, Oklahoma City,(transcription factors); Imperial Cancer Research Fund, London,(DNA repair); University of North Carolina, Chapel Hill, (breastcancer); St. Jude Children's Research Hospital, Memphis, Tenn.,(hematopoiesis and cell cycle); Emory University, Atlanta, (DNRrepair, cardiovascular disease and brain cancer); University of Utah,Salt Lake City, (cardiovascular disease); Beth Israel Hospital, Boston,(calcium regulation, transcription factors and cell signaling);University of Western Ontario, London, Ontario, (calcium regulation);and Roche Institute of Molecular Biology, Nutley, N.J., (transcriptionfactors)."The goal of these agreements," Lorimier said, "is to elucidate thebiological activity of the proteins these genes express and speed theidentification of new diagnostic and therapeutic products." n

-- Charles Craig

(c) 1997 American Health Consultants. All rights reserved.